GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-04-28| Trials & Approvals

FDA Grants AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Its Fifth Breakthrough Label

by Fujie Tham
Share To

AstraZeneca and Daiichi Sankyo secured another FDA Breakthrough Therapy Designation for Enhertu (trastuzumab deruxtecan), after the DESTINY-Breast04 trial demonstrated significantly improved survival in patients with HER2-low metastatic breast cancer.

The DESTINY-Breast04 is the first-ever Phase III HER2-directed therapy trial in patients with HER2-low metastatic breast cancer to show clinically meaningful benefit in progression-free and overall survival compared to standard treatment. While HER2-positive diagnosis takes up around 20% of breast cancer cases, about 55% of primary breast cancers are considered HER2-low (low-level expression of human epidermal growth factor receptor 2, immunohistochemically 1+ or 2+ and lack of HER2 gene amplification measured by in-situ hybridization).

A FDA breakthrough label means that a drug could offer remarkably better treatment for a serious condition and address a significant unmet medical need. Boasting this designation, novel therapeutics are fast-tracked by the FDA and benefit from advanced development with a six-month review period.

Related Article: Recent Advances in Breast Cancer Treatments: An Overview

 

An ADC Drug Targeting HER-2 Expressing Cells

 

Enhertu is a HER2-directed antibody-drug conjugate (ADC) for treating unresectable or metastatic HER2-positive breast cancer types, consisting of a HER2 monoclonal antibody attached to a potent topoisomerase I inhibitor payload connected by a tumor-selective cleavable linker. 

Susan Galbraith, Executive Vice President of AstraZeneca Oncology R&D said: “Today’s news is a significant validation of the potential we see for the historic DESTINY-Breast04 trial to enable a paradigm shift in how breast cancer is classified by targeting the full spectrum of HER2 expression.” 

Credit Suisse analysts said the expansion of Enhertu’s use for HER2-low cancers could increase sales by $3 billion, fulfilling the multibillion-dollar predictions that prompted AstraZeneca to pay $1.4 billion upfront to Japan’s Daiichi Sankyo for licensing rights to the drug in a deal that could value up to $6.9 billion.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
Easing the Mental Health Burden: How MDMA, Psilocybin, and Other Psychedelics May Open Doors for Treating PTSD, Addiction, and Autism
2025-01-28
Drug Promotion, Nonprescription Pathways, and Advanced Manufacturing: FDA’s Key Focus Areas in 2024 and What’s Next for 2025
2025-01-23
LATEST
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top